FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of
FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and
borderline resectable (BR) pancreatic cancer.